Mohit Bansal
Stock Analyst at Wells Fargo
(3.97)
# 579
Out of 4,987 analysts
170
Total ratings
59%
Success rate
8.67%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Overweight | $240 → $260 | $222.47 | +16.87% | 10 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $27 → $35 | $24.85 | +40.85% | 5 | Sep 11, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Overweight | $26 → $50 | $39.27 | +27.32% | 2 | Sep 11, 2025 | |
| MIST Milestone Pharmaceuticals | Initiates: Overweight | $4 | $1.92 | +108.33% | 1 | Sep 11, 2025 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Overweight | $460 | $383.12 | +20.07% | 11 | Aug 6, 2025 | |
| BNTX BioNTech SE | Maintains: Overweight | $170 → $150 | $96.22 | +55.89% | 2 | Aug 5, 2025 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $97 → $90 | $81.51 | +10.42% | 11 | Jul 30, 2025 | |
| REGN Regeneron Pharmaceuticals | Downgrades: Equal-Weight | $700 → $580 | $591.99 | -2.03% | 18 | May 30, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $50 → $47 | $36.95 | +27.20% | 2 | May 13, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $60 → $65 | $77.81 | -16.46% | 7 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $62 → $53 | $45.02 | +17.73% | 9 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $7 → $1 | $1.41 | -29.08% | 4 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $970 → $1,100 | $751.99 | +46.28% | 17 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $140 | $114.09 | +22.71% | 11 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $165 → $140 | $142.50 | -1.75% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $130 → $170 | $128.30 | +32.50% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $335 → $280 | $285.41 | -1.90% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $18.89 | +58.81% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $25.59 | +173.54% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $90 | $54.36 | +65.56% | 5 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $24.03 | +24.84% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $145.23 | +17.06% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $13.97 | +13,321.62% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $2.28 | +1,478.95% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $12.50 | +52.00% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $5 | $0.14 | +3,362.60% | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.14 | +5,163.16% | 4 | Dec 3, 2019 |
AbbVie
Sep 12, 2025
Maintains: Overweight
Price Target: $240 → $260
Current: $222.47
Upside: +16.87%
Travere Therapeutics
Sep 11, 2025
Maintains: Overweight
Price Target: $27 → $35
Current: $24.85
Upside: +40.85%
Mineralys Therapeutics
Sep 11, 2025
Maintains: Overweight
Price Target: $26 → $50
Current: $39.27
Upside: +27.32%
Milestone Pharmaceuticals
Sep 11, 2025
Initiates: Overweight
Price Target: $4
Current: $1.92
Upside: +108.33%
Vertex Pharmaceuticals
Aug 6, 2025
Upgrades: Overweight
Price Target: $460
Current: $383.12
Upside: +20.07%
BioNTech SE
Aug 5, 2025
Maintains: Overweight
Price Target: $170 → $150
Current: $96.22
Upside: +55.89%
Merck & Co.
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $97 → $90
Current: $81.51
Upside: +10.42%
Regeneron Pharmaceuticals
May 30, 2025
Downgrades: Equal-Weight
Price Target: $700 → $580
Current: $591.99
Upside: -2.03%
Xenon Pharmaceuticals
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $36.95
Upside: +27.20%
Halozyme Therapeutics
May 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $65
Current: $77.81
Upside: -16.46%
Apr 28, 2025
Maintains: Equal-Weight
Price Target: $62 → $53
Current: $45.02
Upside: +17.73%
Apr 15, 2025
Downgrades: Equal-Weight
Price Target: $7 → $1
Current: $1.41
Upside: -29.08%
Mar 5, 2025
Maintains: Overweight
Price Target: $970 → $1,100
Current: $751.99
Upside: +46.28%
Mar 5, 2025
Maintains: Overweight
Price Target: $120 → $140
Current: $114.09
Upside: +22.71%
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $165 → $140
Current: $142.50
Upside: -1.75%
Feb 13, 2025
Upgrades: Overweight
Price Target: $130 → $170
Current: $128.30
Upside: +32.50%
Jan 10, 2025
Maintains: Equal-Weight
Price Target: $335 → $280
Current: $285.41
Upside: -1.90%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $18.89
Upside: +58.81%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $25.59
Upside: +173.54%
Sep 17, 2024
Maintains: Overweight
Price Target: $115 → $90
Current: $54.36
Upside: +65.56%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $24.03
Upside: +24.84%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $145.23
Upside: +17.06%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $13.97
Upside: +13,321.62%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $2.28
Upside: +1,478.95%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $12.50
Upside: +52.00%
Apr 27, 2020
Maintains: Buy
Price Target: $8 → $5
Current: $0.14
Upside: +3,362.60%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.14
Upside: +5,163.16%